India Pharma Outlook Team | Friday, 10 October 2025
Turbine, a prominent company focused on the virtualization of biological experiments using AI, has announced a partnership with AstraZeneca to evaluate the capability of Turbine’s platform in rationalizing the discovery of antibody-drug conjugates (ADCs) by predicting response mechanisms, guiding ADC positioning, and minimizing the necessity for extensive cell line screenings.
This partnership will utilize Turbine’s platform, which enables the virtualization of biological experiments on a large scale, to enhance both the efficiency and speed of ADC discovery while also providing mechanistic insights that are often absent in current experimental screening methods.
ADCs represent targeted cancer therapies that deliver powerful drug payloads directly to tumor cells; however, the discovery process can be hindered by the requirement to identify effective payloads across various tumor types and patient demographics through expensive, large-scale screenings involving hundreds of cell lines and patient-derived xenografts (PDXs).
Also Read: Jubilant HollisterStier Unveils High-Speed Isolator Line
Through this collaboration, Turbine and AstraZeneca aim to tackle the in vitro challenges by employing a lab-in-the-loop strategy, where Turbine’s platform suggests a carefully selected subset of cell lines for testing, subsequently predicting outcomes across thousands of in silico models utilizing AstraZeneca’s ADC datasets, which encompass both single-agent and combination studies.“By implementing a lab-in-the-loop approach, we can move beyond broad experimental screening toward a more efficient, targeted strategy that selects the ADC combinations most likely to succeed in patients,” said Daniel Veres, MD, PhD, CSO and co-founder of Turbine. “This also lays the groundwork for deeper integration of our Virtual Lab into discovery workflows, helping ensure that the right experiments are run to generate the greatest impact for patients.”
